Fig. 6: The Akt2 inhibitor enhances the FoxO3a/Bim signaling pathway in lymphocytes and reverses GC resistance. | Cell Death & Disease

Fig. 6: The Akt2 inhibitor enhances the FoxO3a/Bim signaling pathway in lymphocytes and reverses GC resistance.

From: Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal

Fig. 6

a Analysis by western blot of Akt1, p-Akt1 (Ser473), Akt2, and p-Akt2 (Ser474) in CCRF-CEM ALL cells treated with DEX, the Akt isoform inhibitors, or DEX plus the Akt inhibitors. b–d Western blot analysis and relative quantification of FoxO3a/Bim signaling proteins in CCRF-CEM ALL cells treated with DEX, Akt1 inhibitor, Akt2 inhibitor or Akt1/2 inhibitor, or DEX plus Akt1 inhibitor, Akt2 inhibitor or Akt1/2 inhibitor. Bar graphs in b–d represent mean ± SD

Back to article page